# ADC Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adc-therapeutics

- Industry: Biotechnology
- Headquarters: Lausanne, Switzerland
- Website: www.adctherapeutics.com
- Total disclosed funding: $280M
- Latest round: Series E (Oct 23, 2017)
- Investors on record: 5

## About

Founded in 2011 and based in Lausanne, Switzerland, ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company with research and development operations in London, clinical and commercial operations in New Jersey, and CMC (chemistry, manufacturing and controls) operations in the San Francisco Bay Area. The company was founded by Chief Executive Officer and Director Chris Martin, former co-founder of Spirogen Ltd. who led numerous collaboration transactions, including agreements with Genentech and Seattle Genetics. In July 2019, ADC Therapeutics SA raised USD 103 million in series E funding from unspecified investors. Also, the company became a public entity in May 2020 where Deerfield Partners provided USD 65 million convertible senior notes to support its growth.

The firm focuses on the development and commercialization of highly potent and targeted antibody-drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. The company's product candidates include loncastuximab tesirine-lpyl, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, and ADCT-701.

## Funding rounds

- Series E, Oct 23, 2017, $200M — AstraZeneca, Auven Therapeutics, Redmile Group, 4BIO Capital Partners, Wild Family Office
- Series B, Sep 2, 2015, $80M — AstraZeneca, Auven Therapeutics, 4BIO Capital Partners

## Investors

- AstraZeneca — Series B, Series E
- Auven Therapeutics (https://capitalatlas.ai/funds/auven-therapeutics) — Series B, Series E
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Series B, Series E
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series E
- Wild Family Office — Series E